1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
Macias, M.J.
Aragon, E.
Goerner, N.
Zaromytidou, A.
Xi, Q.
Escobedo, A.
Massague, J.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
C3 H7 N O2
89.093
y
ALANINE
L-peptide linking
C6 H15 N4 O2 1
175.209
y
ARGININE
L-peptide linking
C4 H8 N2 O3
132.118
y
ASPARAGINE
L-peptide linking
C4 H7 N O4
133.103
y
ASPARTIC ACID
L-peptide linking
C5 H10 N2 O3
146.144
y
GLUTAMINE
L-peptide linking
C5 H9 N O4
147.129
y
GLUTAMIC ACID
L-peptide linking
C2 H5 N O2
75.067
y
GLYCINE
peptide linking
C6 H10 N3 O2 1
156.162
y
HISTIDINE
L-peptide linking
C6 H13 N O2
131.173
y
ISOLEUCINE
L-peptide linking
C6 H13 N O2
131.173
y
LEUCINE
L-peptide linking
C6 H15 N2 O2 1
147.195
y
LYSINE
L-peptide linking
C5 H11 N O2 S
149.211
y
METHIONINE
L-peptide linking
C9 H11 N O2
165.189
y
PHENYLALANINE
L-peptide linking
C5 H9 N O2
115.130
y
PROLINE
L-peptide linking
C3 H8 N O6 P
185.072
n
PHOSPHOSERINE
PHOSPHONOSERINE
L-peptide linking
C3 H7 N O3
105.093
y
SERINE
L-peptide linking
C4 H9 N O3
119.119
y
THREONINE
L-peptide linking
C11 H12 N2 O2
204.225
y
TRYPTOPHAN
L-peptide linking
C9 H11 N O3
181.189
y
TYROSINE
L-peptide linking
C5 H11 N O2
117.146
y
VALINE
L-peptide linking
US
Genes Dev.
GEDEEP
2056
0890-9369
25
1275
1288
10.1101/gad.2060811
21685363
A Smad action turnover switch operated by WW domain readers of a phosphoserine code.
2011
10.2210/pdb2laj/pdb
pdb_00002laj
5210.877
E3 ubiquitin-protein ligase NEDD4-like
6.3.2.-
WW 3 domain residues 496-535
1
man
polymer
1112.966
Mothers against decapentaplegic homolog 3
sequence database residues 202-211
1
syn
polymer
NEDD4.2, Nedd4-2
MAD homolog 3, Mad3, Mothers against DPP homolog 3, hMAD-3, JV15-2, SMAD family member 3, SMAD 3, Smad3, hSMAD3
no
no
GAMEQSFLPPGWEMRIAPNGRPFFYDHNTKTTTWEDPRLKFPVH
GAMEQSFLPPGWEMRIAPNGRPFFYDHNTKTTTWEDPRLKFPVH
A
polypeptide(L)
no
yes
AG(SEP)PNL(SEP)PNP
AGSPNLSPNP
B
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
human
sample
NEDD4L, KIAA0439, NEDL3
9606
Homo sapiens
511693
Escherichia coli
BL21
petM11
Third WW domain of human Nedd4L (residues 476-515) in complex with doubly phosphorylated human smad3 derived peptide (residues 202-211).
database_2
pdbx_database_status
pdbx_nmr_software
struct_conn
struct_ref_seq_dif
repository
Initial release
Version format compliance
Data collection
Database references
Derived calculations
Other
1
0
2011-07-06
1
1
2011-07-13
1
2
2023-06-14
_database_2.pdbx_DOI
_database_2.pdbx_database_accession
_pdbx_database_status.status_code_nmr_data
_pdbx_nmr_software.name
_struct_conn.pdbx_leaving_atom_flag
_struct_ref_seq_dif.details
BMRB
Y
RCSB
2011-03-16
REL
REL
REL
REL
9606
human
Homo sapiens
sample
448
0
237
53
174
structures with acceptable covalent geometry
300
15
2D 1H-1H NOESY
2D 1H-1H TOCSY
3D CBCA(CO)NH
3D HNCACB
2D 1H-15N HSQC
1
mM
3
mM
20
mM
100
mM
2
mM
1
mM
[U-100% 15N]
3
mM
20
mM
100
mM
2
mM
1
mM
[U-100% 13C; U-100% 15N]
3
mM
20
mM
100
mM
2
mM
0.420
7
ambient
285
K
simulated annealing
1
lowest energy
1 mM NEDD4LWW3, 3 mM SMAD3, 20 mM sodium phosphate, 100 mM sodium chloride, 2 mM sodium azide, 90% H2O/10% D2O
90% H2O/10% D2O
1 mM [U-100% 15N] NEDD4LWW3, 3 mM SMAD3, 20 mM sodium phosphate, 100 mM sodium chloride, 2 mM sodium azide, 90% H2O/10% D2O
90% H2O/10% D2O
1 mM [U-100% 13C; U-100% 15N] NEDD4LWW3, 3 mM SMAD3, 20 mM sodium phosphate, 100 mM sodium chloride, 2 mM sodium azide, 90% H2O/10% D2O
90% H2O/10% D2O
Brunger, Adams, Clore, Gros, Nilges and Read
structure solution
CNS
1.3
Bartels et al.
chemical shift assignment
XEASY
Bruker Biospin
collection
TopSpin
Delaglio, Grzesiek, Vuister, Zhu, Pfeifer and Bax
processing
NMRPipe
Brunger, Adams, Clore, Gros, Nilges and Read
refinement
CNS
1.3
600
Bruker
DRX
Bruker DRX
n
1
472
A
n
2
473
A
n
3
474
A
n
4
475
A
GLN
476
n
5
GLN
476
A
SER
477
n
6
SER
477
A
PHE
478
n
7
PHE
478
A
LEU
479
n
8
LEU
479
A
PRO
480
n
9
PRO
480
A
PRO
481
n
10
PRO
481
A
GLY
482
n
11
GLY
482
A
TRP
483
n
12
TRP
483
A
GLU
484
n
13
GLU
484
A
MET
485
n
14
MET
485
A
ARG
486
n
15
ARG
486
A
ILE
487
n
16
ILE
487
A
ALA
488
n
17
ALA
488
A
PRO
489
n
18
PRO
489
A
ASN
490
n
19
ASN
490
A
GLY
491
n
20
GLY
491
A
ARG
492
n
21
ARG
492
A
PRO
493
n
22
PRO
493
A
PHE
494
n
23
PHE
494
A
PHE
495
n
24
PHE
495
A
TYR
496
n
25
TYR
496
A
ASP
497
n
26
ASP
497
A
HIS
498
n
27
HIS
498
A
ASN
499
n
28
ASN
499
A
THR
500
n
29
THR
500
A
LYS
501
n
30
LYS
501
A
THR
502
n
31
THR
502
A
THR
503
n
32
THR
503
A
THR
504
n
33
THR
504
A
TRP
505
n
34
TRP
505
A
GLU
506
n
35
GLU
506
A
ASP
507
n
36
ASP
507
A
PRO
508
n
37
PRO
508
A
ARG
509
n
38
ARG
509
A
LEU
510
n
39
LEU
510
A
LYS
511
n
40
LYS
511
A
PHE
512
n
41
PHE
512
A
PRO
513
n
42
PRO
513
A
VAL
514
n
43
VAL
514
A
HIS
515
n
44
HIS
515
A
ALA
202
n
1
ALA
202
B
GLY
203
n
2
GLY
203
B
SEP
204
n
3
SEP
204
B
PRO
205
n
4
PRO
205
B
ASN
206
n
5
ASN
206
B
LEU
207
n
6
LEU
207
B
SEP
208
n
7
SEP
208
B
PRO
209
n
8
PRO
209
B
ASN
210
n
9
ASN
210
B
PRO
211
n
10
PRO
211
B
author_defined_assembly
2
dimeric
B
SEP
204
PHOSPHOSERINE
B
SEP
3
SER
B
SEP
208
PHOSPHOSERINE
B
SEP
7
SER
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
x,y,z
identity operation
0.0000000000
0.0000000000
0.0000000000
A
N
ALA
488
A
N
ALA
17
A
O
ARG
492
A
O
ARG
21
A
N
PHE
495
A
N
PHE
24
A
O
THR
504
A
O
THR
33
1
A
GLY
472
A
GLY
1
1
Y
1
A
ALA
473
A
ALA
2
1
Y
1
A
MET
474
A
MET
3
1
Y
1
A
GLU
475
A
GLU
4
1
Y
2
A
GLY
472
A
GLY
1
1
Y
2
A
ALA
473
A
ALA
2
1
Y
2
A
MET
474
A
MET
3
1
Y
2
A
GLU
475
A
GLU
4
1
Y
3
A
GLY
472
A
GLY
1
1
Y
3
A
ALA
473
A
ALA
2
1
Y
3
A
MET
474
A
MET
3
1
Y
3
A
GLU
475
A
GLU
4
1
Y
4
A
GLY
472
A
GLY
1
1
Y
4
A
ALA
473
A
ALA
2
1
Y
4
A
MET
474
A
MET
3
1
Y
4
A
GLU
475
A
GLU
4
1
Y
5
A
GLY
472
A
GLY
1
1
Y
5
A
ALA
473
A
ALA
2
1
Y
5
A
MET
474
A
MET
3
1
Y
5
A
GLU
475
A
GLU
4
1
Y
6
A
GLY
472
A
GLY
1
1
Y
6
A
ALA
473
A
ALA
2
1
Y
6
A
MET
474
A
MET
3
1
Y
6
A
GLU
475
A
GLU
4
1
Y
7
A
GLY
472
A
GLY
1
1
Y
7
A
ALA
473
A
ALA
2
1
Y
7
A
MET
474
A
MET
3
1
Y
7
A
GLU
475
A
GLU
4
1
Y
8
A
GLY
472
A
GLY
1
1
Y
8
A
ALA
473
A
ALA
2
1
Y
8
A
MET
474
A
MET
3
1
Y
8
A
GLU
475
A
GLU
4
1
Y
9
A
GLY
472
A
GLY
1
1
Y
9
A
ALA
473
A
ALA
2
1
Y
9
A
MET
474
A
MET
3
1
Y
9
A
GLU
475
A
GLU
4
1
Y
10
A
GLY
472
A
GLY
1
1
Y
10
A
ALA
473
A
ALA
2
1
Y
10
A
MET
474
A
MET
3
1
Y
10
A
GLU
475
A
GLU
4
1
Y
11
A
GLY
472
A
GLY
1
1
Y
11
A
ALA
473
A
ALA
2
1
Y
11
A
MET
474
A
MET
3
1
Y
11
A
GLU
475
A
GLU
4
1
Y
12
A
GLY
472
A
GLY
1
1
Y
12
A
ALA
473
A
ALA
2
1
Y
12
A
MET
474
A
MET
3
1
Y
12
A
GLU
475
A
GLU
4
1
Y
13
A
GLY
472
A
GLY
1
1
Y
13
A
ALA
473
A
ALA
2
1
Y
13
A
MET
474
A
MET
3
1
Y
13
A
GLU
475
A
GLU
4
1
Y
14
A
GLY
472
A
GLY
1
1
Y
14
A
ALA
473
A
ALA
2
1
Y
14
A
MET
474
A
MET
3
1
Y
14
A
GLU
475
A
GLU
4
1
Y
15
A
GLY
472
A
GLY
1
1
Y
15
A
ALA
473
A
ALA
2
1
Y
15
A
MET
474
A
MET
3
1
Y
15
A
GLU
475
A
GLU
4
1
Y
1
A
A
HD11
HG2
LEU
PRO
479
508
1.30
2
B
B
H3
O3P
ALA
SEP
202
204
1.56
3
A
A
HG3
HE1
PRO
PHE
480
512
1.34
3
B
B
H2
O1P
ALA
SEP
202
204
1.56
4
A
A
HD11
HG2
LEU
PRO
479
508
1.31
5
A
A
HG3
HE1
PRO
PHE
480
512
1.23
5
A
A
HZ2
HZ3
TRP
LYS
483
511
1.23
5
B
B
H3
O3P
ALA
SEP
202
204
1.60
8
A
A
HG3
HE1
PRO
PHE
480
512
1.19
8
A
B
HD22
O1P
ASN
SEP
490
208
1.55
9
A
A
HD13
HG2
LEU
PRO
479
508
1.30
9
A
A
HE3
HG12
LYS
VAL
511
514
1.32
9
A
A
HE2
HB2
PHE
MET
478
485
1.33
10
A
A
HG3
HE1
PRO
PHE
480
512
1.19
11
A
A
HG3
HE1
PRO
PHE
480
512
1.10
11
A
A
OD1
HZ3
ASP
LYS
497
511
1.59
12
A
B
HD22
O1P
ASN
SEP
490
208
1.50
12
B
B
H2
O1P
ALA
SEP
202
204
1.58
14
A
B
HG1
HG3
THR
PRO
503
209
1.20
15
A
A
HB2
HB3
GLN
LEU
476
479
1.23
1
A
A
PHE
LEU
478
479
-132.73
1
A
A
GLY
TRP
482
483
-141.84
2
A
A
PHE
LEU
478
479
-134.07
2
A
A
GLY
TRP
482
483
-138.68
3
A
A
PHE
LEU
478
479
-131.71
3
A
A
GLY
TRP
482
483
-143.28
4
A
A
PHE
LEU
478
479
-132.27
4
A
A
GLY
TRP
482
483
-142.03
5
A
A
PHE
LEU
478
479
-131.29
5
A
A
GLY
TRP
482
483
-141.46
6
A
A
PHE
LEU
478
479
-130.29
6
A
A
GLY
TRP
482
483
-140.10
7
A
A
PHE
LEU
478
479
-133.21
7
A
A
GLY
TRP
482
483
-142.54
8
A
A
PHE
LEU
478
479
-130.67
8
A
A
GLY
TRP
482
483
-141.96
9
A
A
PHE
LEU
478
479
-129.79
9
A
A
GLY
TRP
482
483
-142.35
10
A
A
PHE
LEU
478
479
-130.01
10
A
A
GLY
TRP
482
483
-141.88
11
A
A
PHE
LEU
478
479
-130.78
11
A
A
GLY
TRP
482
483
-141.90
12
A
A
PHE
LEU
478
479
-131.45
12
A
A
GLY
TRP
482
483
-141.61
13
A
A
PHE
LEU
478
479
-130.39
13
A
A
GLY
TRP
482
483
-141.03
14
A
A
PHE
LEU
478
479
-131.70
14
A
A
GLY
TRP
482
483
-141.74
15
A
A
PHE
LEU
478
479
-134.57
15
A
A
GLY
TRP
482
483
-144.88
1
-16.66
2.00
110.40
93.74
A
A
A
CB
CA
C
PHE
PHE
PHE
478
478
478
N
1
-5.12
0.70
120.80
115.68
A
A
A
CB
CG
CD2
PHE
PHE
PHE
478
478
478
N
2
-13.33
2.00
110.40
97.07
A
A
A
CB
CA
C
PHE
PHE
PHE
478
478
478
N
3
-14.62
2.00
110.40
95.78
A
A
A
CB
CA
C
PHE
PHE
PHE
478
478
478
N
3
-5.60
0.70
120.80
115.20
A
A
A
CB
CG
CD2
PHE
PHE
PHE
478
478
478
N
4
-14.90
2.00
110.40
95.50
A
A
A
CB
CA
C
PHE
PHE
PHE
478
478
478
N
4
-5.15
0.70
120.80
115.65
A
A
A
CB
CG
CD2
PHE
PHE
PHE
478
478
478
N
5
-14.80
2.00
110.40
95.60
A
A
A
CB
CA
C
PHE
PHE
PHE
478
478
478
N
5
-5.81
0.70
120.80
114.99
A
A
A
CB
CG
CD2
PHE
PHE
PHE
478
478
478
N
6
-12.88
2.00
110.40
97.52
A
A
A
CB
CA
C
PHE
PHE
PHE
478
478
478
N
6
-4.92
0.70
120.80
115.88
A
A
A
CB
CG
CD2
PHE
PHE
PHE
478
478
478
N
7
-16.53
2.00
110.40
93.87
A
A
A
CB
CA
C
PHE
PHE
PHE
478
478
478
N
7
-4.41
0.70
120.80
116.39
A
A
A
CB
CG
CD2
PHE
PHE
PHE
478
478
478
N
8
-13.81
2.00
110.40
96.59
A
A
A
CB
CA
C
PHE
PHE
PHE
478
478
478
N
8
-6.06
0.70
120.80
114.74
A
A
A
CB
CG
CD2
PHE
PHE
PHE
478
478
478
N
9
-13.98
2.00
110.40
96.42
A
A
A
CB
CA
C
PHE
PHE
PHE
478
478
478
N
9
-5.91
0.70
120.80
114.89
A
A
A
CB
CG
CD2
PHE
PHE
PHE
478
478
478
N
9
9.32
1.50
119.30
128.62
A
A
A
C
N
CA
PHE
PRO
PRO
512
513
513
Y
10
-14.63
2.00
110.40
95.77
A
A
A
CB
CA
C
PHE
PHE
PHE
478
478
478
N
11
-14.18
2.00
110.40
96.22
A
A
A
CB
CA
C
PHE
PHE
PHE
478
478
478
N
11
-6.04
0.70
120.80
114.76
A
A
A
CB
CG
CD2
PHE
PHE
PHE
478
478
478
N
12
-15.66
2.00
110.40
94.74
A
A
A
CB
CA
C
PHE
PHE
PHE
478
478
478
N
12
-5.40
0.70
120.80
115.40
A
A
A
CB
CG
CD2
PHE
PHE
PHE
478
478
478
N
12
4.39
0.70
120.80
125.19
A
A
A
CB
CG
CD1
PHE
PHE
PHE
494
494
494
N
13
-14.44
2.00
110.40
95.96
A
A
A
CB
CA
C
PHE
PHE
PHE
478
478
478
N
13
-4.52
0.70
120.80
116.28
A
A
A
CB
CG
CD2
PHE
PHE
PHE
478
478
478
N
14
-15.11
2.00
110.40
95.29
A
A
A
CB
CA
C
PHE
PHE
PHE
478
478
478
N
14
-5.35
0.70
120.80
115.45
A
A
A
CB
CG
CD2
PHE
PHE
PHE
478
478
478
N
15
-14.52
2.00
110.40
95.88
A
A
A
CB
CA
C
PHE
PHE
PHE
478
478
478
N
15
-5.40
0.70
120.80
115.40
A
A
A
CB
CG
CD2
PHE
PHE
PHE
478
478
478
N
1
A
PRO
480
-59.89
174.05
1
A
PRO
481
-79.30
38.30
1
A
PRO
489
-56.36
1.86
1
A
PRO
513
-48.96
-9.63
1
B
PRO
205
-59.62
100.03
1
B
LEU
207
-63.21
99.24
2
A
PRO
481
-88.59
30.16
2
A
PRO
489
-54.38
2.78
2
A
PRO
513
-48.73
-9.51
2
A
VAL
514
-58.22
-9.67
2
B
PRO
205
-59.53
98.22
3
A
PRO
481
-79.52
29.15
3
A
PRO
489
-55.95
0.94
3
A
PRO
513
-50.86
-9.70
3
B
PRO
205
-59.68
98.48
4
A
PRO
480
-59.82
173.96
4
A
PRO
481
-78.22
36.00
4
A
PRO
489
-54.96
-3.78
4
A
PHE
512
-39.63
-39.69
4
A
PRO
513
-49.63
-9.61
4
A
VAL
514
-57.47
-9.50
4
B
PRO
205
-59.58
106.24
5
A
PRO
480
-59.78
171.54
5
A
PRO
481
-74.79
28.83
5
A
PRO
489
-57.67
-2.19
5
A
PRO
513
-50.40
-9.85
5
A
VAL
514
-59.96
-9.61
6
A
SER
477
-120.15
-75.24
6
A
PRO
481
-80.17
34.86
6
A
PRO
489
-52.68
-4.11
6
A
PRO
513
-48.06
-9.42
6
A
VAL
514
-57.35
-9.86
6
B
PRO
205
-59.63
106.25
6
B
LEU
207
-61.47
99.89
7
A
PRO
481
-78.12
36.74
7
A
PRO
489
-57.83
5.44
7
A
ASN
499
-164.60
-74.43
7
A
PHE
512
-39.96
-32.08
7
A
PRO
513
-46.95
-8.90
7
A
VAL
514
-46.43
-9.86
7
B
PRO
205
-59.65
105.68
8
A
PRO
480
-59.80
171.82
8
A
PRO
481
-77.51
24.48
8
A
PRO
489
-57.61
-4.16
8
A
PHE
512
-39.67
-39.31
8
A
PRO
513
-50.98
-9.62
8
B
PRO
205
-59.62
102.76
9
A
PRO
480
-59.91
174.38
9
A
PRO
481
-74.43
24.62
9
A
PRO
489
-52.78
-3.19
9
A
PRO
513
-42.81
-8.92
9
A
VAL
514
-45.39
-9.74
9
B
PRO
205
-59.60
106.09
10
A
PRO
480
-59.86
170.65
10
A
PRO
481
-77.09
35.07
10
A
PRO
489
-58.82
5.73
10
B
PRO
205
-59.98
105.70
11
A
SER
477
-96.92
-75.25
11
A
PRO
480
-59.95
175.28
11
A
PRO
481
-79.22
30.68
11
A
PRO
489
-59.70
3.20
11
B
PRO
205
-59.41
100.39
12
A
PRO
481
-78.74
34.61
12
A
PRO
489
-56.90
1.79
12
A
PRO
513
-46.63
-9.70
12
B
PRO
205
-59.67
109.68
13
A
PRO
489
-54.55
-4.57
13
A
PHE
512
-39.36
-33.58
13
A
PRO
513
-43.76
-9.13
13
A
VAL
514
-48.02
-9.82
14
A
PRO
481
-79.23
36.02
14
A
PRO
489
-58.00
4.28
14
A
PHE
512
-39.33
-35.76
14
A
PRO
513
-42.51
-8.88
14
A
VAL
514
-41.45
-9.73
14
B
PRO
205
-59.54
98.83
15
A
PRO
480
-59.93
172.65
15
A
PRO
481
-74.42
29.16
15
A
PRO
489
-54.41
-2.51
15
A
PHE
512
-39.65
-38.11
15
A
PRO
513
-45.87
-9.84
15
B
PRO
205
-59.86
108.04
N
lowest energy, model 1
Third WW domain of human Nedd4L in complex with doubly phosphorylated human smad3 derived peptide
1
N
N
2
N
N
A
ASP
507
A
ASP
36
HELX_P
A
HIS
515
A
HIS
44
5
1
9
covale
1.318
both
B
GLY
203
B
C
GLY
2
1_555
B
SEP
204
B
N
SEP
3
1_555
covale
1.336
both
B
SEP
204
B
C
SEP
3
1_555
B
PRO
205
B
N
PRO
4
1_555
covale
1.325
both
B
LEU
207
B
C
LEU
6
1_555
B
SEP
208
B
N
SEP
7
1_555
covale
1.344
both
B
SEP
208
B
C
SEP
7
1_555
B
PRO
209
B
N
PRO
8
1_555
LIGASE/TRANSCRIPTION REGULATOR
CDK, signal transduction, LIGASE-TRANSCRIPTION REGULATOR complex
NED4L_HUMAN
UNP
1
496
Q96PU5
QSFLPPGWEMRIAPNGRPFFIDHNTKTTTWEDPRLKFPVH
SMAD3_HUMAN
UNP
2
202
P84022
AGSPNLSPNP
496
535
2LAJ
476
515
Q96PU5
A
1
5
44
202
211
2LAJ
202
211
P84022
B
2
1
10
1
expression tag
GLY
472
2LAJ
A
Q96PU5
UNP
1
1
expression tag
ALA
473
2LAJ
A
Q96PU5
UNP
2
1
expression tag
MET
474
2LAJ
A
Q96PU5
UNP
3
1
expression tag
GLU
475
2LAJ
A
Q96PU5
UNP
4
1
ILE
engineered mutation
TYR
496
2LAJ
A
Q96PU5
UNP
516
25
3
anti-parallel
anti-parallel
A
TRP
483
A
TRP
12
A
ALA
488
A
ALA
17
A
ARG
492
A
ARG
21
A
ASP
497
A
ASP
26
A
THR
502
A
THR
31
A
THR
504
A
THR
33